Aniket๐๐ฎ๐ป ๐ฏ๐ถ๐ผ๐๐ถ๐บ๐ถ๐น๐ฎ๐ฟ๐ ๐บ๐ฎ๐ธ๐ฒ ๐ฎ๐ฑ๐๐ฎ๐ป๐ฐ๐ฒ๐ฑ ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ถ๐ฒ๐ ๐บ๐ผ๐ฟ๐ฒ ๐ฎ๐ณ๐ณ๐ผ๐ฟ๐ฑ๐ฎ๐ฏ๐น๐ฒ?
Governments like South Korea are introducing pricing caps on ๐ฏ๐ถ๐ผ๐๐ถ๐บ๐ถ๐น๐ฎ๐ฟ๐, ๐ถ๐บ๐ฝ๐ฟ๐ผ๐๐ถ๐ป๐ด ๐ฎ๐ฐ๐ฐ๐ฒ๐๐๐ถ๐ฏ๐ถ๐น๐ถ๐๐ ๐ฎ๐ป๐ฑ ๐ฏ๐ผ๐ผ๐๐๐ถ๐ป๐ด ๐ฎ๐ฑ๐ผ๐ฝ๐๐ถ๐ผ๐ป across APAC.
๐ฅ๐ฒ๐ฎ๐ฑ ๐บ๐ผ๐ฟ๐ฒ: https://www.kenresearch.com/industry-reports/asia-pacific-biopharmaceuticals-market?utm_source=Mastadon&utm_medium=Social&utm_campaign=Aniket
QuamedMillions still lack access to life-saving medicines, not because science failed, but because patents, prices, and politics get in the way. This deep dive unpacks how countries have used (and sometimes avoided) TRIPS flexibilities over the past 25 years to break monopolies,
Read more: https://gh.bmj.com/content/11/1/e021481
#AccessToMedicines #TRIPS #PublicHealth #MedicineQuality #GlobalHealth #HealthEquity #GenericMedicines #PharmaPolicy #IPandHealth #Quamed
TRIPS flexibilities help change policy and practice to increase access to medicines: evidence from 2001 to 2024
Introduction Millions of people lack access to safe and effective pharmaceuticals because they are unaffordable or unavailable, particularly in โdevelopingโ and โleast-developedโ countries (DCs, LDCs), and increasingly in high-income countries (HICs). Management of intellectual property (IP) related to new medicines has a significant impact on access to safe, affordable and effective medicines. The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) provides the international legal framework for IP protection and mandates 20-year patents in all technological fields, including pharmaceuticals. TRIPS contains flexibilities, such as compulsory licensing (CL) and transition provisions for LDCs, which governments can use to facilitate access to health technologies. The use of these flexibilities is underreported in the literature, and a thorough analysis has not been undertaken since the COVID-19 pandemic.Methods A scoping review of three medical and legal databases and temporal analysis of all known instances of use or potential use of CLs and the LDC pharmaceutical transition measure between 2001-2024.Results 61% of the 149 CL instances were executed. The relative rates of CL use between countries have shifted: HICs represent over half of CL instances in the last decade. CLs are increasingly considered for chronic, non-communicable and rare diseases. The threat of CL use continues to provide impetus for price negotiations, voluntary licences or other measures to improve access. Almost all eligible countries have invoked the right to use the LDC transition measure.Conclusions TRIPS flexibilities have been used to facilitate access to medicines (including vaccines) over the quarter-century since the adoption of the World Trade Organizationโs Doha Declaration on TRIPS and Public Health. The flexibilities play a vital role in ensuring that new medicines are affordable and are likely to continue to be in a future where geopolitical forces have drastically altered the financing structures of medicines provision in DCs and LDCs.